BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, Blanco JL, León A, Deulofeu R, Miquel R, Milinkovic A, Lonca M, Miró JM, Biglia A, Murillas J, Gatell JM, Mallolas J. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;46:304-11. [PMID: 18172937 DOI: 10.1097/qai.0b013e3181520502] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Pérez-Is L, Collazos J, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, Fonseca-González GJ, Melón S, Valle-Garay E, Asensi V. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci Rep 2022;12:3828. [PMID: 35264591 DOI: 10.1038/s41598-022-07548-y] [Reference Citation Analysis]
2 Koļesova O, Madelāne M, Ekšteina I, Koļesovs A, Krūmiņa A, Vīksna L. The Level of Cytokeratin 18 in Patients with HIV and Viral Hepatitis C Co-Infection in Latvia. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2020;74:94-99. [DOI: 10.2478/prolas-2020-0015] [Reference Citation Analysis]
3 Koļesova O, Eglīte J, Koļesovs A, Krūmiņa A, Ekšteina I, Madelāne M, Vīksna L. Association of Non-Invasive Markers of Liver Fibrosis with HCV Coinfection and Antiretroviral Therapy in Patients with HIV. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2019;73:400-402. [DOI: 10.2478/prolas-2019-0062] [Reference Citation Analysis]
4 Singh H, Jadhav S, Samani D, Nain S. Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder. Mediators Inflamm 2019;2019:8278095. [PMID: 31275061 DOI: 10.1155/2019/8278095] [Reference Citation Analysis]
5 Sherman KE, Sterling RK. HIV and the Liver. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00037-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Seang S, Somasunderam A, Nigalye M, Somsouk M, Schacker TW, Sanchez JL, Hunt PW, Utay NS, Lake JE. Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathog Immun 2017;2:239-52. [PMID: 28782046 DOI: 10.20411/pai.v2i2.180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45 [PMID: 28573088 DOI: 10.5501/wjv.v6.i2.36] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Latronico T, Mascia C, Pati I, Zuccala P, Mengoni F, Marocco R, Tieghi T, Belvisi V, Lichtner M, Vullo V, Mastroianni CM, Liuzzi GM. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. Int J Mol Sci. 2016;17:455. [PMID: 27023536 DOI: 10.3390/ijms17040455] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
9 Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016;89:24-31. [PMID: 27004022 DOI: 10.15386/cjmed-554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
10 Zhuravlyova A, Kharkiv National Medical University, Ogneva O, Kharkiv National Medical University.. Modern possibilities of diagnosis and quantification of liver fibrosis. Shidnoevr z vnutr simejnoi med 2015;2015:55-60. [DOI: 10.15407/internalmed2015.02.055] [Reference Citation Analysis]
11 Jansen C, Leeming DJ, Mandorfer M, Byrjalsen I, Schierwagen R, Schwabl P, Karsdal MA, Anadol E, Strassburg CP, Rockstroh J, Peck-Radosavljevic M, Møller S, Bendtsen F, Krag A, Reiberger T, Trebicka J. PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. PLoS One 2014;9:e108544. [PMID: 25265505 DOI: 10.1371/journal.pone.0108544] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
12 Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, Asensi V. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012;19:685-93. [PMID: 22967099 DOI: 10.1111/j.1365-2893.2012.01596.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
13 Peters L, Neuhaus J, Mocroft A, Soriano V, Rockstroh J, Dore G, Puoti M, Tedaldi E, Clotet B, Kupfer B, Lundgren JD, Klein MB; SMART Study Group. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther 2011;16:667-75. [PMID: 21817188 DOI: 10.3851/IMP1815] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
14 Smith JO, Sterling RK. Noninvasive Markers of Liver Injury and Fibrosis. HIV and Liver Disease 2012. [DOI: 10.1007/978-1-4419-1712-6_5] [Reference Citation Analysis]
15 Connoy A, Turner J, Núñez M. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use. AIDS Res Hum Retroviruses 2011;27:719-25. [PMID: 21128862 DOI: 10.1089/AID.2010.0224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
16 Diaz A, García F, Mozos A, Caballero M, León A, Martinez A, Gil C, Plana M, Gallart T, Gatell JM, Alós L. Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors. J Infect Dis 2011;203:810-3. [PMID: 21343147 DOI: 10.1093/infdis/jiq129] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
17 Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, Labarga P, Medrano J, González-Lahoz J, Soriano V. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011;18:11-6. [PMID: 20088890 DOI: 10.1111/j.1365-2893.2009.01261.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
18 Resino S, Bellón JM, Asensio C, Micheloud D, Miralles P, Vargas A, Catalán P, López JC, Alvarez E, Cosin J. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis. 2010;10:244. [PMID: 20723207 DOI: 10.1186/1471-2334-10-244] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
19 Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh CR Jr, Cotton D. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010;105:1346-53. [PMID: 20179698 DOI: 10.1038/ajg.2009.746] [Cited by in Crossref: 121] [Cited by in F6Publishing: 117] [Article Influence: 9.3] [Reference Citation Analysis]
20 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557-76. [PMID: 19519733 DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
21 Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Muga R. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 2009;16:513-8. [PMID: 19200132 DOI: 10.1111/j.1365-2893.2009.01103.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
22 Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45. [PMID: 19171202 DOI: 10.1016/j.cgh.2008.11.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
23 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134:1670-81. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 298] [Cited by in F6Publishing: 320] [Article Influence: 19.9] [Reference Citation Analysis]